相关实验视频

Updated: Jul 8, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

针对HER2的附属体分子99mTc-ABH2用于对乳腺癌中HER2表达的成像

Xiaona Jin¹, Yuwei Zhang¹, Xi Cao²

¹From the Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China.

Clinical nuclear medicine

|December 3, 2024

概括

99mTc-ABH2 SPECT/CT显示出准确评估乳腺癌中人类表皮生长因子受体2型 (HER2) 状态的前景. 这种成像技术准确地识别了HER2阳性瘤和转移,有助于治疗决策.

科学领域:

核医学是一种核医学.
在瘤学瘤学.
放射性药物放射性药物放射性药物

背景情况:

准确的HER2状态评估对于指导乳腺癌中的HER2向疗法至关重要.
目前的诊断方法在预测治疗反应方面存在局限性.
对于精确的体内HER2评估,需要新的成像剂.

研究的目的:

评估99mTc-ABH2 SPECT/CT用于乳腺癌中HER2表达的安全性,可行性和诊断准确性.
为了比较99mTc-ABH2 SPECT/CT与18F-FDG PET/CT的性能.
根据已建立的诊断标准 (免疫组织化学和FISH) 验证成像结果.

主要方法:

一项前性研究,涉及36名怀疑患有原发性乳腺癌的患者.
使用99mTc-ABH2和18F-FDG PET/CT进行SPECT/CT成像.
用免疫组织化学和光 in situ 杂交对成像发现的验证.

主要成果:

99mTc-ABH2 SPECT/CT在注射后2小时左右实现了最佳的对比度.
视觉评估显示71.4%的灵敏度和72.2%的特异性.
使用SUVmax切割值 (2.32) 进行定量分析,结果为92.86%的灵敏度,72.22%的特异性和81.25%的准确性.
99mTc-ABH2精确识别了HER2 (3+) 瘤,并检测了骨/淋巴结转移.
18F-FDG PET/CT没有区分HER2 (2+/3+) 和HER2 (0/1+) 瘤 (P = 0.81).

结论:

99mTc-ABH2 SPECT/CT是一种有前途的工具,用于精确的体内HER2评估乳腺癌.
对HER2 (3+) 瘤的高度敏感性和转移的可视化强调了它的诊断价值.
这种技术有可能对患者管理和治疗结果产生积极影响.

更多相关视频

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Determining Binding Affinity KD of Radiolabeled Antibodies to Immobilized Antigens

Published on: June 23, 2022

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET